BCM
FLGT icon

Bayesian Capital Management’s Fulgent Genetics FLGT Stock Holding History

Bayesian Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,265
Closed -$239K – 886
2023
Q4 		$239K Buy
+8,265
New +$221K 0.03% 559
2022
Q3 		– Sell
-8,700
Closed -$474K – 803
2022
Q2 		$474K Buy
+8,700
New +$478K 0.09% 350
2021
Q3 		– Sell
-3,816
Closed -$352K – 439
2021
Q2 		$352K Sell
3,816
-5,735
-60% -$458K 0.09% 241
2021
Q1 		$923K Buy
9,551
+3,751
+65% +$387K 0.21% 128
2020
Q4 		$302K Buy
+5,800
New +$242K 0.08% 301

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bayesian Capital Management's FLGT Position: Q1 2024 in Review

Bayesian Capital Management sold out of Fulgent Genetics (FLGT) in Q1 2024, closing a stake of 8,265 shares — an estimated $239K sold.

Bayesian Capital Management first reported a position in FLGT in Q4 2020 and held it in 5 quarters. The position peaked at $923K in Q1 2021. 180 funds tracked by Wall St. Rank hold FLGT as of Q1 2024.

  • Bayesian Capital Management reported no remaining Fulgent Genetics position as of Q1 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 8,265 Fulgent Genetics shares in Q1 2024, an estimated $239K.
  • Bayesian Capital Management first reported a position in Fulgent Genetics in Q4 2020 and held it in 5 quarters.
  • Bayesian Capital Management's Fulgent Genetics position peaked at $923K in Q1 2021.
  • 180 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2024.

Based on Bayesian Capital Management's 13F filing for Q1 2024, filed 15 May 2024.